Responders vs clinical response: a critical analysis of data from linaclotide phase 3 clinical trials in IBS-C

BACKGROUND: US Food and Drug Administration (FDA) set a rigorous standard for defining patient responders in irritable bowel syndrome-C (IBS-C; i.e., FDA's Responder Endpoint) for regulatory approval. However, this endpoint's utility for health-care practitioners to assess clinical respons...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Neurogastroenterol Motil
Hlavní autoři: Lacy, B E, Lembo, A J, MacDougall, J E, Shiff, S J, Kurtz, C B, Currie, M G, Johnston, J M
Médium: Artigo
Jazyk:Inglês
Vydáno: BlackWell Publishing Ltd 2014
Témata:
Original Articles
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC4282394/
https://ncbi.nlm.nih.gov/pubmed/24382134
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/nmo.12264
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky